Project Grant R37CA317219
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $611K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
- The National Institutes of Health National Cancer Institute awarded Fred Hutchinson Cancer Center $692,368 on June 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate the MYC transcription factor network and its role in oncogenic and tumor-suppressive pathways. The research examines how dysregulation of MYC family transcription factors drives cancer initiation, progression, immune escape, and chemoresistance. The project uses genetically engineered...
- The National Cancer Institute awarded Fred Hutchinson Cancer Center $139,680 on January 18, 2026, under the Cancer Research Manpower program (CFDA 93.398) to characterize tumor-specific human endogenous retroviruses (HERVs) in clear cell renal cell carcinoma. The project measures HERV expression in clear cell renal cell carcinoma (CCRCC), which accounts for 80% of renal cancer cases, using a comprehensive HERV database (HERVDB) to investigate the role of abnormally activated HERVs in tumor...
- The National Institutes of Health National Cancer Institute awarded Fred Hutchinson Cancer Center $723,547 on June 9, 2026, under the Cancer Biology Research program (CFDA 93.396) to delineate the role of 5' untranslated regions in prostate cancer clonality. The research addresses the heterogeneity of prostate cancer within individual patients through investigation of how untranslated regions modulate clonal growth in prostate cancer cells. Preliminary work conducted an unbiased 5' UTR tiled...
- The National Cancer Institute awarded Fred Hutchinson Cancer Center $752,751 on July 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to decipher tumor heterogeneity, metastatic spread, and treatment resistance in advanced bladder cancer through the Fred Hutch/UW Bladder Cancer Rapid Autopsy Program. The project builds on an existing resource established in 2015 that collects tumors and matched benign tissues from metastatic bladder cancer patients within hours of death, with...
- The National Cancer Institute awarded Fred Hutchinson Cancer Center $716,319 on June 11, 2026, under the Cancer Treatment Research program (CFDA 93.395) to optimize CD45-targeted astatine-211 radioimmunotherapy for malignant and non-malignant blood disorders. The funded work focuses on developing and refining astatine-211 (211AT) radioisotope-conjugated monoclonal antibodies targeting CD45, an antigen expressed on hematopoietic cells. The research builds on prior Phase 3 trial validation of...
- The National Cancer Institute awarded Fred Hutchinson Cancer Center $192,024 under the Cancer Research Manpower program (CFDA 93.398) on July 16, 2026, to support research on synthetic costimulation and signaling calibration for chimeric T cell receptors. The project, identified as K22CA303684, advances bispecific chimeric T cell receptor (BI-CHTCR) engineering to overcome limitations in current CAR T cell therapies for B cell malignancies. Existing CAR T cells frequently relapse due to...
- The National Cancer Institute awarded Fred Hutchinson Cancer Center $712,569 on May 4, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the impact of KEAP1/NRF2 pathway activation on chemotherapy response in small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). The research tests whether NRF2 activation or deletion governs cisplatin-etoposide (CIS-ETO) response in patient-derived xenograft (PDX) models of SCLC and LCNEC, with the primary...
- The National Cancer Institute awarded Fred Hutchinson Cancer Center $727,971 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to characterize the tumor-associated microbiome in early-onset rectal cancers and elucidate the microenvironment of this emerging disease. The award funds a five-year research project (August 1, 2026 through July 31, 2031) examining distinctive microbial features—both bacterial and fungal—in early-onset cancers of the sigmoid colon...
- The National Cancer Institute awarded a $695,155 Cooperative Agreement to Fred Hutchinson Cancer Center on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to optimize post-transplantation cyclophosphamide (PTCY) dosing for hematopoietic cell transplantation with peripheral blood stem cell grafts. The award funds a phase I/II clinical trial examining PTCY dose de-escalation in recipients of HLA-matched or HLA-haploidentical donor transplants using reduced-intensity...
- Federal Cooperative Agreement Summary Fred Hutchinson Cancer Center received a $4.23 million Cooperative Agreement from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to conduct comprehensive characterization of the T-cell immune response to Kaposi Sarcoma Herpesvirus (KSHV). The award, effective September 19, 2025 through August 31, 2029, supports research aimed at enabling specific immune therapies for KSHV-associated diseases. The project focuses...